Klisarovska, Violeta
Preferred name
Klisarovska, Violeta
Official Name
Klisarovska, Violeta
Translated Name
Виолета Клисаровска
Alternative Name
Виолета Клисаровска
Klisarovska, V.
Klisarovav V.
V. Klisarovska
V. Klisarova
Klisarovska V.
Violeta Klisarovska
Main Affiliation
Email
vikiklisarovska@yahoo.com
36 results
Now showing 1 - 10 of 36
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, 8034 POSTER Capecitabine as Second- and Third-line Chemotherapy in the Treatment of Platinum-refractory Epithelial Ovarian Cancer(Elsevier BV, 2011-09); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Клиничка релевантност за инхибиција на ангиогенезата кај карцином на овариум(3rd International Congress of Gynecologists and Obstetricians of Macedonia, 2013-05) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, CONTACT BRACHYTHERAPY IN THE TREATMENT OF SUPERFICIAL NON-MELANOMA SKIN CANCER: SINGLE INSTITUTIONAL EXPERIENCE(Macedonian Association of Anatomists and Morphologists, 2024); Introduction: Contact brachytherapy allows satisfactory treatment of superficial non-melanoma skin cancer, whether as adjuvant and/or definitive therapy. There are different techniques and different dose prescriptions in clinical practice, adapted to technical possibilities. Material and methods: 50 patients treated with contact brachytherapy for superficial non-melanoma skin cancer were analyzed, 15 of them in a postoperative and 35 in a definitive setting. Histopathologically, 40 patients had verified basal cell carcinoma and 10 had squamous cell carcinoma. High dose rate brachytherapy was performed with the GammaMed Plustm, with a radioactive Iridium192. A Leipzig-style cone contact applicator set with a diameter range of 10-45 mm was used. In 40 patients, a hypofractionated regimen was performed, with one fraction per week, with a dose of 7Gy, a total of 4 fractions, to achieve a total dose of 28Gy, over 4 weeks. A dose of 30Gy with a single fraction of 5Gy, over 6 weeks was administered to 10 patients, respectively, regardless of histological type. The dose was prescribed to a depth of 5 mm of the skin. Results: Local control was confirmed in 47 patients. In 3 patients the disease recurred 10 months after the last treatment (7Gy/4fr/28Gy). Skin redness was manifested in all patients (100%). Telangiectasia presented at the end of the treatment in 4 patients. At the first visit, all patients had reduced or completely disappeared inflammatory reactions. Conclusion: Our experience with the use of hypofractionated regimens has shown that it is a safe treatment, with easily manageable side effects. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Dosimetric comparison of two-dimensional versus three-dimensional intracavitary brachytherapy in locally advanced cervical cancer(National Library of Serbia, 2018); ; ; Dimitrovska, Nadica - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epthelial ovarian cancer in premenopausal women d biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women(Japan Society of Obstetrics and Gynecology, 2017-12); Marko StanojevicAim: This study is a comparison of human epididymis protein 4 (HE4) with cancer antigen 125 (CA125), using the Risk of Ovarian Malignancy Algorithm (ROMA), Copenhagen Index (CPH-I), Risk of Malignancy Index (RMI) and Morphology Index (MI) to differentiate ovarian endometriosis from epithelial ovarian cancer (EOC) in premenopausal women. Methods: The study was performed at the University Clinic of Obstetrics and Gynecology in Skopje. One hundred and sixty-four premenopausal patients were divided into three study groups, including ovarian endometriosis (37), other benign pelvic masses (57) and EOCs (11), and a control group (59). After ultrasonography, all subjects underwent blood sampling. Surgery and histological verification was performed. Pelvic masses were classified based on histological findings. Mann–Whitney, receiver operating characteristicarea under the curve (AUC), sensitivity, specificity and Kruskal–Wallis tests were used for statistical analysis. The level of significance α was set at 5%. Results: For each of the tested markers, sensitivity, specificity and accuracy to distinguish ovarian endometriosis from EOC were as follows: HE4 (81.82%, 100%, 95.83%); CA125 (81.82%, 48.65%, 56.25%); ROMA (90.91%, 83.78%, 85.42%); CPH-I (81.82%, 97.30%, 93.75%); RMI (90.91%, 35.14%, 47.92%); and MI (100%, 75.68%, 81.25%), respectively. The AUC for ovarian endometriosis compared to EOC for tested markers was as follows: HE4 (AUC = 0.934), CA125 (AUC = 0.821), ROMA (AUC = 0.929), CPH-I (AUC = 0.924) and RMI (AUC = 0.880), respectively. Conclusion: HE4 and CPH-I perform best to discriminate ovarian endometriosis from EOC in premenopausal women. MI has maximal sensitivity to detect EOC. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Concurrent chemoradiotherapy in locally and/or regionally advanced nasopharyngeal carcinoma(2008-12); ; The aim of the study was to investigate the efficacy of concurrent chemoradiotherapy (CCRT) in patients with locally and/or regionally advanced nasopharyngeal carcinoma (NPC). Between February 2005 and November 2007, 27 patients with advanced NPC were included in a prospective study of CCRT at the Radiotherapy and Oncology Institute in Skopje. Radiotherapy was performed using a sophisticated three-dimensional conformal technique. A dose of 69.4-71.4 Gy (median, 69.4 Gy) was delivered to the primary tumour and to the positive neck nodes. Chemotherapy consisted of cisplatin 30 mg/m(2) given concomitantly with radiation on a weekly basis. The median age was 49 years and 51.2% had stage IV disease. Eighty-eight percent received >or= 5 cycles of concurrent cisplatin. Complete response rates three months after chemoradiotherapy completion were 81.5% (22 of 27) and 91.3% (21 of 23) at the primary site and in the neck, respectively. Only one patient had a locoregional relapse and four patients developed distant metastases. The most prevalent grade 3 acute effect was mucositis present in 63.0% of patients. The 2-year disease-free survival (DFS) rate was 42.6%, the 2-year locoregional relapse-free survival (LR-RFS) rate was 76.9%, and the 2-year distant metastases relapse-free survival (DM-RFS) rate was 63.6%. Considering the preliminary results of our study which do not indicate that the therapeutic effects of CCRT evaluated are comparable with the results from the randomised phase III studies, we recommend an effort for the routine use of the new radiotherapy technique, intensity-modulated radiation therapy (IMRT), as well as an initiation of a phase III trial addressing the definition of the precise role of sequential chemotherapy in the management of patients with locally advanced NPC. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Dosimetric evaluation of two intracavitary brachytherapy modalities in treatment of inoperable cervical cancer(Eight international conference on radiation in varoius fields of research, 2020-07-24); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Orbital Metastasis as Primary Presentation of Misdiagnosed Breast Cancer: A Case Report(Juniper Publishers, 2019-11-15); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, THE INFLUENCE OF ANESTHESIA IN INTRACAVITARY BRACHYTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER - SINGLE INSTITUTIONAL EXPERIENCE(Department of Anesthesia and Reanimation, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 2018-05); ; ; Lazareva E.Brachytherapy is important and potentially curative treatment for patients with inoperable locally advanced cervical cancer. Depending on the local finding the radioactive source application can cause serious discomfort to the patient, anxiety, followed by pain. Some patients experienced severe uterine pain. In selected patients, anesthesiological assessment and support is of great importance, because this is a way to realized the treatment. Because of that the anesthesiologist is a vital member of the brachytherapy team. Anaesthesiologists play a key role in the ongoing challenge to provide safe and pain-free conditions for an optimum brachytherapy treatment effect. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, INTRAVAGINAL BRACHYTHERAPY SUPPORTED BY LOCAL ANAESTHESIA IN THE TREATMENT OF ENDOMETRIAL CANCER – SINGLE INSTITUTIONAL EXPERIENCE(Department of Anaesthesia and Reanimation, Faculty of Medicine, “Ss. Cyril and Methodius” University Skopje, R.N.Macedonia, 2020-10); ; ; ; Bojoski PIntravaginal brachytherapy in endometrial cancer is an inevitable part of the treatment. In the early stages of the disease, it signifcantly reduces the risk of local recurrence in the vaginal cuff with low rates of late toxicity. In the advanced stages, it provides palliative control usually with a hemostyptic effect. Brachytherapy may be the only postoperative treatment – monotherapy, or as a boost following the external beam radiotherapy, depending on many prognostic factors. Placing the vaginal applicator deep into the vagina is certainly an uncomfortable feeling, combined with pain, anxiety and discomfort. Local anaesthesia helps in reducing the painful sensations, gives adequate relaxation, but more importantly provides a quality insight into the condition of the vagina, and thus a successful application. Through our experience with the local vaginal anaesthesia with lidocaine 2% gel, we want to emphasize that intravaginal brachytherapy, supported by local anaesthesia, regardless of the degree of pain relief is directly related to successful treatment.